Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery.
DEL technology is evolving into a powerful tool for drug discovery, particularly for challenging targets, with AI integration being a key advancement.
Where it sits
this study against the rest of the cerebrolysin corpusSummary and findings
The paper reviews the evolution of DNA-encoded library (DEL) technology in drug discovery, focusing on challenging targets over the past fifteen years. It discusses advancements in DEL's application to GTPases, epigenetic regulators, phosphatases, protein-protein interactions, membrane proteins, and RNA. Methodological breakthroughs and future directions for DEL are highlighted.
Abstract
DNA-encoded library (DEL) technology has emerged as a transformative platform in early-stage drug discovery, enabling the rapid and cost-effective exploration of ultra-large chemical spaces. However, identifying ligands for challenging targets characterized by featureless surfaces, high conformational plasticity, or shallow binding sites remains a formidable challenge. While the potential of DEL is widely recognized, a systematic evaluation of its strategic evolution against these intractable targets over the past fifteen years is timely. This review surveys the progress of DEL technology in tackling such targets, organized by GTPases, epigenetic regulators, phosphatases, protein-protein interaction (PPI), membrane proteins, and RNA. We highlight pivotal case studies and methodological breakthroughs while critically examining aspects of driving force in DEL such as DNA-compatible chemistry, diversified library design, advanced selection strategies, and artificial intelligence (AI) integration. Finally, we illustrate how DEL evolves from a conventional screening tool into a multifaceted discovery engine. By identifying future directions that include expanding three-dimensional chemical space, enhancing library fidelity, and deepening integration with functional biology and AI, this review provides a strategic roadmap to inspire and guide future DEL campaigns against those challenging targets.
Background
DNA-encoded library (DEL) technology is a significant advancement in drug discovery, allowing for the exploration of vast chemical spaces. Despite its potential, identifying ligands for targets with complex characteristics remains challenging. This study reviews the strategic evolution of DEL technology, which is crucial for understanding its current capabilities and future potential.
Methods
This is a review article that systematically evaluates the progress of DEL technology over the past fifteen years. It organizes findings by target categories such as GTPases, epigenetic regulators, phosphatases, protein-protein interactions, membrane proteins, and RNA. The review highlights case studies and methodological advancements without conducting new experiments.
Results
The review identifies several methodological breakthroughs in DEL technology, including the integration of artificial intelligence and advancements in DNA-compatible chemistry. It also notes the evolution of DEL from a conventional screening tool to a comprehensive discovery engine. Specific quantitative results or new experimental data are not provided.
Interpretation
The review suggests that DEL technology has made significant strides in addressing challenging drug discovery targets. However, the lack of new experimental data limits the ability to assess the clinical significance of these advancements. The integration of AI and expansion into three-dimensional chemical space are promising directions but require further exploration.
Key findings
- DEL technology enables exploration of ultra-large chemical spaces.
- Challenges include featureless surfaces and high conformational plasticity.
- DEL has evolved from a screening tool to a discovery engine.
- Integration with AI is a significant methodological breakthrough.
- Future directions include expanding three-dimensional chemical space.
Limitations
- Review article, no new experimental data
- Focuses on methodological advancements rather than outcomes
- Limited to existing literature without new quantitative findings